Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments

1
Multiple Myeloma Therapeutics in Major Developed
Markets to 2021 - Growth Driven by Rising
Prevalence, Continued Success of Revlimid and
Emerging Supplementary Treatments
Single User License - 4995 Site User License
- 9990 Corporate User License -
14985 Publication Date - Jul 2015 Pages -
119 To know more details, email to
debora_at_reportstack.com
2
Summary

• Multiple Myeloma (MM) is a hematological
  malignancy characterized by the proliferation of
  plasma cells in the bone marrow. It is the
  second-most frequently diagnosed hematological
  malignancy, with an annual prevalence in the US
  of about 45,000. The disease is considered
  incurable, although the past decade has seen
  significant improvements in therapy, driven by a
  greater understanding of pathophysiology. Many of
  the leading drugs in the market were approved
  over the past 1015 years, and have improved
  median survival rates by about 50.

3
Scope

• The MM market landscape has undergone significant
  change over the past two decades.
• Which classes of drug have emerged to dominate
  the market?
• What survival benefits have these drugs
  produced?
• How do the leading marketed therapies compare
  clinically?
• The pipeline contains a range of molecule types
  and molecular targets not present in the current
  market, including a strong focus on therapies
  targeting common oncogenic pathways, such as the
  Phosphoinositide 3-Kinase/Protein Kinase B
  (PI3K/Akt) pathway.

4
Key Benefits

• Understand the current clinical and commercial
  landscape through a comprehensive study of
  disease pathogenesis, diagnosis, prognosis, and
  the current treatment algorithm used in MM.
• Assess the safety and efficacy of current
  treatment options, with extensive product
  profiles on prominent marketed therapies and a
  heatmap directly comparing safety and efficacy
  data. 
• Analyze the MM pipeline and stratify by stage of
  development, molecule type, and molecular target.
  The most promising late-stage therapies are
  profiled and assessed in terms of clinical
  performance and competitiveness, alongside a
  single-product forecast.

5
If you are interested...
Contact Debora White Email
debora_at_reportstack.com Ph1-888-789-6604 http/
/www.reportstack.com